Designer interface peptide grafts target estrogen receptor alpha dimerization.

Area of Science:

• Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• Estrogen receptor alpha (ERα) is a nuclear transcription factor crucial for cellular signaling and a validated target in 70% of breast cancers.
• Anti-estrogen therapies are effective but face significant challenges due to acquired resistance.
• ERα dimerization is essential for its activation, making it a potential target to overcome resistance.

Purpose of the Study:

• To investigate novel strategies for blocking ERα dimerization to combat anti-estrogen resistance in breast cancer.
• To design and evaluate grafted peptides that preserve pharmacophoric recognition motifs for ERα dimerization inhibition.

Main Methods:

• Comprehensive molecular simulations were used to study ERα LBDs (ligand-binding domains) homo-dimer interaction dynamics.
• Identification of three interface recognition peptide motifs: LDKITDT, LQQQHQRLAQ, and LSHIRHMSNK.
• In silico and in vitro assessment of stability and efficacy of grafted peptides designed to block ERα dimerization.

Main Results:

• Grafted peptides successfully blocked ERα-mediated cell proliferation and viability in breast cancer cells.
• The identified peptide motif LQQQHQRLAQ (ERα residues 497-506) showed suitability as a template for inhibitor design.
• The grafted peptides did not alter the apoptotic fate of the breast cancer cells.

Conclusions:

• Grafted peptides targeting the ERα dimer interface represent a promising complementary strategy against anti-estrogen resistant breast cancer.
• Structural insights from this study can guide the development of novel peptidomimetics and small molecules.
• This approach aims to generate a new class of anti-cancer agents specifically targeting ERα dimerization.